Haemonetics upgraded by BofA Securities with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for HAE
Across the 15 sessions after earlier HAE headlines, the stock closed higher 10 times and lower 5 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HAE | SPY |
|---|---|---|---|
| May 12, 2026 | Barrington Research reiterated coverage on Haemonetics with a new price target | +3.4% | -0.2% |
| May 7, 2026 | Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website | +3.2% | -0.3% |
| May 5, 2026 | Haemonetics to Present at Bank of America 2026 Healthcare Conference | +0.5% | +0.8% |
| Apr 24, 2026 | New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures | +0.5% | +0.8% |
| Apr 2, 2026 | Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026 | +1.0% | +0.1% |
| Mar 31, 2026 | Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System | +2.6% | +2.9% |
Quantisnow market dataNYSE
HAE
Haemonetics Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 1991
Get push alerts for HAE
Full HAE profile on Quantisnow Follow HAE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time